Gr. T. Popa University of Medicine and Pharmacy;St. Spiridon Emergency Hospital, Institute of Gastroenterology and Hepatology, Iasi, Romania.
St. Spiridon Emergency Hospital, Institute of Gastroenterology and Hepatology, Iasi, Romania.
J Gastrointestin Liver Dis. 2015 Dec;24(4):423-8. doi: 10.15403/jgld.2014.1121.244.csd.
Patients with liver cirrhosis are at-risk population for Clostridium difficile infection (CDI). There is a paucity of data on the incidence of CDI in cirrhotics with hepatic encephalopathy (HE). The aim of the study was to evaluate the incidence and risk factors for CDI in cirrhotics hospitalized with HE.
A retrospective analysis of all cirrhotics with HE admitted at a tertiary referral center from January 2012 to December 2014 was made. Patients' medical charts were reviewed, and demographics, laboratory parameters, antibiotics use, etiology of cirrhosis, and therapy of HE, as well as the results of stool samples for toxins A and B (enzyme immunoassay) were carefully searched. The presence of toxin A or B (or both) in stool samples was defined as CDI. Data on cirrhotics with HE and CDI (study group) were compared with those from patients without CDI (control group).
A total of 231 cirrhotic patients were hospitalized with HE mostly stage 2 and 3, and 17 (7.3%) of them were diagnosed with CDI. The overall CDI incidence rate was 57.2 cases per 10,000 patient-days. As compared with control patients, those with HE and CDI were more likely to have older age, increased serum creatinine level, hepatorenal syndrome (HRS), and more prior hospitalizations. On multivariate analysis, antibiotic therapy, age over 65 years, and HRS remained significantly related with the development of CDI.
Hospitalized cirrhotics with HE are at risk for developing CDI, and clinicians treating such patients should be aware of this infection as rapid detection and prompt treatment may improve outcomes.
肝硬化患者是艰难梭菌感染(CDI)的高危人群。肝性脑病(HE)合并肝硬化患者中 CDI 的发病率数据较少。本研究旨在评估住院伴有 HE 的肝硬化患者 CDI 的发生率和危险因素。
对 2012 年 1 月至 2014 年 12 月在一家三级转诊中心住院的所有伴有 HE 的肝硬化患者进行回顾性分析。查阅患者病历,仔细检索人口统计学、实验室参数、抗生素使用、肝硬化病因、HE 治疗以及粪便毒素 A 和 B 检测(酶联免疫吸附试验)结果。粪便样本中存在毒素 A 或 B(或两者)定义为 CDI。将伴有 HE 和 CDI 的肝硬化患者(研究组)的数据与无 CDI 的患者(对照组)进行比较。
共有 231 例肝硬化患者因 HE 住院,HE 分期多为 2 期和 3 期,其中 17 例(7.3%)诊断为 CDI。总的 CDI 发生率为 57.2 例/10000 患者日。与对照组患者相比,伴有 HE 和 CDI 的患者年龄更大,血清肌酐水平更高,肝肾综合征(HRS)发生率更高,住院次数更多。多变量分析显示,抗生素治疗、年龄>65 岁和 HRS 与 CDI 的发生显著相关。
住院伴有 HE 的肝硬化患者存在发生 CDI 的风险,治疗此类患者的临床医生应意识到这种感染,因为快速检测和及时治疗可能会改善预后。